{
  "abstract": "Background: Immunoglobulin E (IgE) is increasingly recognized as a component of immune surveillance with potential relevance to cancer biology. While elevated IgE has been studied in relation to cancer risk, the implications of ultra-low or deficient total serum IgE remain unclear.\n\nMethods: We conducted a systematic review of observational studies examining ultra-low or deficient total serum IgE and cancer risk, searching PubMed/MEDLINE and Embase through September 2026. We additionally conducted exploratory analyses among 26,676 adults in the Swedish Apolipoprotein-related Mortality RISk (AMORIS) cohort with baseline total serum IgE measurements. Cancer risk was assessed using Cox proportional hazards models adjusted for age, sex, and education. IgE was analyzed using clinically defined categories (<2, 2–10, 10–20, 20–100, 100–<1,000, ≥1,000kU/L).\n\nResults: Seven observational studies met inclusion criteria. Several studies reported higher cancer prevalence or risk among individuals with ultra-low or deficient IgE, although studies were heterogeneous and largely retrospective or unadjusted. In exploratory AMORIS analyses, there was no evidence of an increased overall cancer risk among individuals with IgE deficiency (<2kU/L).\n\nConclusion: Existing studies suggest a possible association between ultra-low total serum IgE and cancer risk, but current evidence is limited. In exploratory AMORIS cohort analyses, there was no evidence of an increased overall cancer risk among individuals with IgE deficiency. Further prospective studies with repeated IgE measurements and comprehensive covariate data are needed to clarify this understudied association.",
  "abstract_shown": true,
  "affiliations": [
    "Transforming Cancer OUtcomes through Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London",
    "St. John’s Institute of Dermatology, School of Basic and Medical Biosciences and King's Health Partners (KHP) Centre for Translational Medicine, Guy’s Hospital, King’s College London",
    "Barcelona Institute for Global Health (ISGlobal)",
    "Universitat Pompeu Fabra (UPF)",
    "Centro de Investigación Biomédica en Red (CIBER) Epidemiología y Salud Pública (CIBERESP)",
    "Neuro-Immunology Group, Department of Cancer Research, Luxembourg Institute of Health",
    "Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet",
    "Department of Internal Medicine/Allergy and Immunology, Albert Einstein College of Medicine, Montefiore Medical Center",
    "Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King’s College London, Innovation Hub, Guy’s Cancer Centre"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 15,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Maria J. Monroy-Iglesias"
    },
    {
      "affs": [
        0
      ],
      "name": "Gincy George"
    },
    {
      "affs": [
        0
      ],
      "name": "Isolt Reardon"
    },
    {
      "affs": [
        1
      ],
      "name": "Jitesh Chauhan"
    },
    {
      "affs": [
        1
      ],
      "name": "Heather J. Bax"
    },
    {
      "affs": [
        1
      ],
      "name": "Alexandra McCraw"
    },
    {
      "affs": [
        2,
        3,
        4
      ],
      "name": "Michelle C. Turner"
    },
    {
      "affs": [
        5
      ],
      "name": "Aurélie Poli"
    },
    {
      "affs": [
        6
      ],
      "name": "Niklas Hammar"
    },
    {
      "affs": [
        6
      ],
      "name": "Maria Feychting"
    },
    {
      "affs": [
        6
      ],
      "name": "Mats Talbäck"
    },
    {
      "affs": [
        7
      ],
      "name": "Denisa E. Ferastraoaru"
    },
    {
      "affs": [
        0
      ],
      "name": "Aida Santaolalla"
    },
    {
      "affs": [
        1,
        8
      ],
      "name": "Sophia N. Karagiannis"
    },
    {
      "affs": [
        0
      ],
      "name": "Mieke Van Hemelrijck"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/66vaezwvx3zra.bib",
  "cited_by": 0,
  "doi": "10.3389/fimmu.2026.1812536",
  "fulltext_url": null,
  "id": "66vaezwvx3zra",
  "issns": [
    "1664-3224"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1812536/full",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2403|Immunodeficiency and Autoimmune Disorders"
    ]
  ],
  "openalex": "W7223177139",
  "pdf_url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1812536/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-22",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/66vaezwvx3zra.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:17Z",
      "native_id": "10.3389/fimmu.2026.1812536",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1812536/full"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2403|Immunodeficiency and Autoimmune Disorders",
      "subfield": "immunology"
    }
  ],
  "title": "Ultra-low values of total serum immunoglobulin E and cancer risk: a systematic review and exploratory analysis of the Swedish AMORIS cohort",
  "title_text": "Ultra-low values of total serum immunoglobulin E and cancer risk: a systematic review and exploratory analysis of the Swedish AMORIS cohort",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:17Z",
  "url": "https://research.draconitic.com/paper/66vaezwvx3zra",
  "venue": "Frontiers in Immunology",
  "versions": []
}